Ionis Pharmaceuticals said the FDA approved a label expansion for Tryngolza (formerly known in development as an antisense drug targeting triglycerides), widening its use in patients with severely high fat molecules and related conditions. The update expands Tryngolza’s commercial opportunity beyond its earlier approved population and reinforces Ionis’ position in RNA-targeting therapies. The approval comes as the company continues to expand the addressable market for antisense medicines in cardiometabolic disease, where treatment uptake depends heavily on payer coverage and clear prescribing guidance. Ionis’ next milestones will likely hinge on how the revised label translates into prescribing behavior in the broader lipid-management segment.